Drug Profile
TNF-SAM2
Alternative Names: Recombinant tumour necrosis factor-TNF-SAM2Latest Information Update: 30 Aug 2002
Price :
$50
*
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Antineoplastics; Tumour necrosis factors
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 02 Jun 1999 A clinical study has been added to the adverse events, pharmacodynamics and therapeutic trials sections
- 02 Jun 1999 A clinical study has been added to the therapeutic trials section
- 05 May 1999 A clinical study has been added to the therapeutic trials, adverse events and pharmacodynamics sections